GSK Reaches Settlement in Illinois Zantac Lawsuit
By Najat Kantouar
GSK said it reached a confidential settlement with a plaintiff over its discontinued drug Zantac, resolving the case in an Illinois state court.
The British pharmaceutical company said Friday that it won't admit any liability in this settlement, and added that the scientific consensus didn't find any consistent or reliable evidence that ranitidine, commonly sold under the brand name Zantac, increases the risk of any cancer.
In 2020, the U.S. Food and Drug Administration requested manufacturers take Zantac off the market. The FDA concluded that the drug's ingredient, ranitidine, can form a cancer-causing contaminant, N-Nitrosodimethylamine, over time or through heat exposure.
GSK said that it would continue to vigorously defend itself and manage this litigation in the best interests of the company and shareholders.
Write to Najat Kantouar at najat.kantouar@wsj.com
(END) Dow Jones Newswires
June 28, 2024 13:27 ET (17:27 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations